Published in Br J Cancer on September 01, 2001
Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst (2009) 4.42
Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer (2009) 3.99
Recurrent KRAS codon 146 mutations in human colorectal cancer. Cancer Biol Ther (2006) 3.56
Activating K-Ras mutations outwith 'hotspot' codons in sporadic colorectal tumours - implications for personalised cancer medicine. Br J Cancer (2010) 3.25
Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res (2010) 3.24
Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications. J Mol Diagn (2010) 3.12
Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value. Clin Cancer Res (2012) 3.07
KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch (2008) 2.78
The chromosomal instability pathway in colon cancer. Gastroenterology (2010) 2.59
Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol (2009) 2.48
KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin Cancer Res (2009) 2.02
Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers. Clin Cancer Res (2012) 1.95
Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases. Cancer (2013) 1.94
A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes. BMC Cancer (2010) 1.91
Association between molecular subtypes of colorectal cancer and patient survival. Gastroenterology (2014) 1.84
The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma. Gut (2005) 1.73
Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery. Oncologist (2010) 1.72
Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant. Br J Cancer (2009) 1.68
Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy. J Clin Oncol (2013) 1.66
Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes. Gastroenterology (2014) 1.57
KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis. PLoS One (2009) 1.50
Genetics, cytogenetics, and epigenetics of colorectal cancer. J Biomed Biotechnol (2011) 1.50
Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review. Mol Cancer (2014) 1.46
BRAF and KRAS gene mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/IPMC) of the pancreas. Cancer Lett (2006) 1.46
Association Between Specific Mutations in KRAS Codon 12 and Colorectal Liver Metastasis. JAMA Surg (2015) 1.46
KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers. Br J Cancer (2013) 1.41
A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens. Br J Cancer (2012) 1.35
Analytical performance of a PCR assay for the detection of KRAS mutations (codons 12/13 and 61) in formalin-fixed paraffin-embedded tissue samples of colorectal carcinoma. Virchows Arch (2011) 1.35
BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer. Cancer (2014) 1.32
Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer. BMC Cancer (2012) 1.31
Implementing prognostic and predictive biomarkers in CRC clinical trials. Nat Rev Clin Oncol (2011) 1.31
High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade. Blood (2011) 1.28
Molecular virology of hepatitis B virus for clinicians. Clin Liver Dis (2007) 1.28
KRAS mutation and microsatellite instability: two genetic markers of early tumor development that influence the prognosis of colorectal cancer. Ann Surg Oncol (2009) 1.26
A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy. Oncologist (2010) 1.26
Are KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers? Anticancer Agents Med Chem (2012) 1.26
Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer. Br J Cancer (2011) 1.24
KRAS analysis in colorectal carcinoma: analytical aspects of Pyrosequencing and allele-specific PCR in clinical practice. BMC Cancer (2010) 1.22
EGFR Signaling in Colorectal Carcinoma. Patholog Res Int (2011) 1.20
KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma. J Pathol (2013) 1.19
Biomarkers in precision therapy in colorectal cancer. Gastroenterol Rep (Oxf) (2013) 1.15
Optimized allele-specific real-time PCR assays for the detection of common mutations in KRAS and BRAF. J Mol Diagn (2010) 1.12
Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer. Br J Cancer (2010) 1.11
KRAS mutation testing in metastatic colorectal cancer. World J Gastroenterol (2012) 1.11
Cellular senescence predicts treatment outcome in metastasised colorectal cancer. Br J Cancer (2010) 1.09
Dietary, lifestyle and clinicopathological factors associated with BRAF and K-ras mutations arising in distinct subsets of colorectal cancers in the EPIC Norfolk study. BMC Cancer (2010) 1.09
Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancer. J Gastroenterol (2012) 1.08
KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance). Clin Cancer Res (2014) 1.08
Genetic polymorphisms in MicroRNA-related genes as predictors of clinical outcomes in colorectal adenocarcinoma patients. Clin Cancer Res (2012) 1.08
Prognostic and predictive roles of KRAS mutation in colorectal cancer. Int J Mol Sci (2012) 1.07
Differences in survival between colon and rectal cancer from SEER data. PLoS One (2013) 1.06
KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer. Korean J Intern Med (2017) 1.05
CpG island methylation is a common finding in colorectal cancer cell lines. Br J Cancer (2003) 1.04
RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer. Cancer (2014) 1.03
Fast simultaneous detection of K-RAS mutations in colorectal cancer. BMC Cancer (2009) 1.02
KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases. Cancer (2014) 1.02
A comparability study of 5 commercial KRAS tests. Diagn Pathol (2010) 1.02
Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets. Ann Surg Oncol (2014) 1.02
KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer. Br J Cancer (2015) 1.01
Activation of MEK1 or MEK2 isoform is sufficient to fully transform intestinal epithelial cells and induce the formation of metastatic tumors. BMC Cancer (2008) 1.01
KRAS and BRAF mutation analysis in colorectal adenocarcinoma specimens with a low percentage of tumor cells. Mol Diagn Ther (2013) 1.00
Clinical significance of K-ras and BRAF mutations in Chinese colorectal cancer patients. World J Gastroenterol (2011) 1.00
Mutated K-ras(Asp12) promotes tumourigenesis in Apc(Min) mice more in the large than the small intestines, with synergistic effects between K-ras and Wnt pathways. Int J Exp Pathol (2009) 1.00
KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer. J Exp Clin Cancer Res (2014) 0.99
Molecular analysis of the EGFR-RAS-RAF pathway in pancreatic ductal adenocarcinomas: lack of mutations in the BRAF and EGFR genes. Virchows Arch (2006) 0.99
Soluble HMGB1 is a novel adipokine stimulating IL-6 secretion through RAGE receptor in SW872 preadipocyte cell line: contribution to chronic inflammation in fat tissue. PLoS One (2013) 0.98
The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer. BMC Cancer (2013) 0.98
Beyond KRAS: Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer. World J Gastroenterol (2014) 0.97
Mutations in BRAF correlate with poor survival of colorectal cancers in Chinese population. Int J Colorectal Dis (2011) 0.97
Role of Kras status in patients with metastatic colorectal cancer receiving first-line chemotherapy plus bevacizumab: a TTD group cooperative study. PLoS One (2012) 0.96
Targeted therapies in colorectal cancer-an integrative view by PPPM. EPMA J (2013) 0.96
Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy. Br J Cancer (2010) 0.95
Gene expression deregulation by KRAS G12D and G12V in a BRAF V600E context. Mol Cancer (2008) 0.95
KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer. Br J Cancer (2013) 0.94
Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer. Int J Clin Oncol (2012) 0.94
PIK3CA, KRAS, and BRAF mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/C) of the pancreas. Langenbecks Arch Surg (2008) 0.94
Important molecular genetic markers of colorectal cancer. Oncotarget (2016) 0.94
Associations of Ki-ras proto-oncogene mutation and p53 gene overexpression in sporadic colorectal adenomas with demographic and clinicopathologic characteristics. Cancer Epidemiol Biomarkers Prev (2006) 0.94
KRAS mutation detection and prognostic potential in sporadic colorectal cancer using high-resolution melting analysis. Br J Cancer (2010) 0.94
Colorectal carcinomas in MUTYH-associated polyposis display histopathological similarities to microsatellite unstable carcinomas. BMC Cancer (2009) 0.94
Colorectal Cancer Biomarkers: Where Are We Now? Biomed Res Int (2015) 0.92
Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: a single center study. J Transl Med (2012) 0.92
Adjuvant Chemotherapy for Stage II Colon Cancer: The Role of Molecular Markers in Choosing Therapy. Gastrointest Cancer Res (2009) 0.91
Influence of KRAS mutation status in metachronous and synchronous metastatic colorectal adenocarcinoma. Cancer (2012) 0.91
Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas. J Thorac Oncol (2015) 0.90
Predictive and prognostic biomarkers with therapeutic targets in advanced colorectal cancer. World J Gastroenterol (2014) 0.90
Predictive and prognostic factors in colorectal cancer: a personalized approach. Cancers (Basel) (2011) 0.89
High MACC1 expression in combination with mutated KRAS G13 indicates poor survival of colorectal cancer patients. Mol Cancer (2015) 0.89
Prognostic significance of glucose transporter-1 (GLUT1) gene expression in rectal cancer after preoperative chemoradiotherapy. Surg Today (2011) 0.89
Colorectal cancers from distinct ancestral populations show variations in BRAF mutation frequency. PLoS One (2013) 0.88
Distinct chromosomal imbalances in nonpolypoid and polypoid colorectal adenomas indicate different genetic pathways in the development of colorectal neoplasms. Am J Pathol (2003) 0.88
Molecular diagnosis of response to neoadjuvant chemoradiation therapy in patients with locally advanced rectal cancer. J Am Coll Surg (2011) 0.87
Impact of KRAS Mutation Status on Outcomes in Metastatic Colon Cancer Patients without Anti-Epidermal Growth Factor Receptor Therapy. Cancer Res Treat (2013) 0.87
Prognostic biomarkers in colorectal cancer: where do we stand? Virchows Arch (2014) 0.87
Recent approaches to identifying biomarkers for high-risk stage II colon cancer. Surg Today (2012) 0.87
Multiple mutations in the Kras gene in colorectal cancer: review of the literature with two case reports. Int J Colorectal Dis (2011) 0.87
Molecular Genetics of Colorectal Cancer: An Overview. Curr Colorectal Cancer Rep (2006) 0.87
Phase II study of everolimus in patients with metastatic colorectal adenocarcinoma previously treated with bevacizumab-, fluoropyrimidine-, oxaliplatin-, and irinotecan-based regimens. Clin Cancer Res (2013) 0.87
Critical appraisal of the use of regorafenib in the management of colorectal cancer. Cancer Manag Res (2013) 0.87
Why are doctors so unhappy? There are probably many causes, some of them deep. BMJ (2001) 22.59
Evidence based medicine. BMJ (1995) 21.24
The complete nucleotide sequence of the tobacco chloroplast genome: its gene organization and expression. EMBO J (1986) 19.59
Linkage disequilibrium in the human genome. Nature (2001) 17.24
What clinical information do doctors need? BMJ (1996) 16.23
Complete genome sequence of enterohemorrhagic Escherichia coli O157:H7 and genomic comparison with a laboratory strain K-12. DNA Res (2001) 15.22
Three-dimensional structure of myosin subfragment-1: a molecular motor. Science (1993) 14.90
Informed consent: the intricacies. BMJ (1997) 13.97
An ethical code for everybody in health care. BMJ (1998) 9.13
All changed, changed utterly. British medicine will be transformed by the Bristol case. BMJ (1998) 9.08
Growing pressure on BMJ's obituaries. BMJ (1995) 8.92
Authorship: time for a paradigm shift? BMJ (1997) 8.90
Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA (2001) 8.80
A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med (1991) 8.65
The failings of NICE. BMJ (2000) 8.50
The future of medicine. BMJ (1994) 8.14
A good death. An important aim for health services and for us all. BMJ (2000) 8.03
Using evidence to inform health policy: case study. BMJ (2001) 7.99
Positional cloning of the mouse circadian clock gene. Cell (1997) 7.79
Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet (1999) 7.72
Time to face up to research misconduct. BMJ (1996) 7.66
Beyond conflict of interest. Transparency is the key. BMJ (1998) 7.63
Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell (1994) 7.23
Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. J Clin Oncol (2001) 6.83
Meeting the information needs of health workers in developing countries. BMJ (1997) 6.31
The fission yeast cdc18+ gene product couples S phase to START and mitosis. Cell (1993) 6.25
Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science (1997) 6.10
Medicine's core values. BMJ (1994) 5.93
Revel in electronic and paper media. BMJ (2000) 5.82
Synchronous and sequential activation of latently infected Epstein-Barr virus genomes. J Virol (1989) 5.67
Calcium induced release of calcium from the sarcoplasmic reticulum of skinned skeletal muscle fibres. Nature (1970) 5.65
The GMC on performance. BMJ (1992) 5.57
Informed consent: edging forwards (and backwards) BMJ (1998) 5.52
PubMed Central: creating an Aladdin's cave of ideas. BMJ (2001) 5.49
Does Britain need an academy of medicine? BMJ (1996) 5.47
Effect of open peer review on quality of reviews and on reviewers' recommendations: a randomised trial. BMJ (1999) 5.45
The Oct-1 homoeodomain directs formation of a multiprotein-DNA complex with the HSV transactivator VP16. Nature (1989) 5.43
The complete nucleotide sequences of the cloned hepatitis B virus DNA; subtype adr and adw. Nucleic Acids Res (1983) 5.41
Rationing: the search for sunlight. BMJ (1992) 5.26
trans activation of the latent Epstein-Barr virus (EBV) genome after transfection of the EBV DNA fragment. J Virol (1986) 5.25
Publishing information about patients. BMJ (1995) 5.19
The future of healthcare systems. BMJ (1997) 5.14
Prejudice against doctors and students from ethnic minorities. Br Med J (Clin Res Ed) (1987) 5.12
The war on drugs. BMJ (1996) 5.11
Global information flow. BMJ (2000) 5.09
A candidate prostate cancer susceptibility gene at chromosome 17p. Nat Genet (2001) 5.06
What makes a good reviewer and a good review for a general medical journal? JAMA (1998) 5.01
A combined PET/CT scanner for clinical oncology. J Nucl Med (2000) 4.99
Where is the wisdom...? BMJ (1991) 4.85
Medicine and the marginalised. They deserve the best, not the poorest, care. BMJ (2000) 4.80
Recombination and clonal groupings within Helicobacter pylori from different geographical regions. Mol Microbiol (1999) 4.72
Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence. Mol Cell Biol (1996) 4.67
X-ray structures of the myosin motor domain of Dictyostelium discoideum complexed with MgADP.BeFx and MgADP.AlF4-. Biochemistry (1995) 4.64
Time to register randomised trials. The case is now unanswerable. BMJ (1999) 4.55
PFI: perfidious financial idiocy. A "free lunch" that could destroy the NHS. BMJ (1999) 4.54
Moving beyond journals: the future arrives with a crash. BMJ (1999) 4.49
Rationing: the debate we have to have. BMJ (1995) 4.47
Antimicrobial activity of DU-6859, a new potent fluoroquinolone, against clinical isolates. Antimicrob Agents Chemother (1992) 4.43
CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res (1996) 4.42
Time to redefine authorship. BMJ (1996) 4.39
Complete nucleotide sequence of a milk-transmitted mouse mammary tumor virus: two frameshift suppression events are required for translation of gag and pol. J Virol (1987) 4.37
Animal research: the need for a middle ground. BMJ (2001) 4.34
Conflict of interest and the BMJ. BMJ (1994) 4.34
Prison medicine: beginning again. BMJ (1992) 4.29
Caspase-3-generated fragment of gelsolin: effector of morphological change in apoptosis. Science (1997) 4.19
A genomewide screen in multiplex rheumatoid arthritis families suggests genetic overlap with other autoimmune diseases. Am J Hum Genet (2001) 4.17
Measuring the social impact of research. BMJ (2001) 4.17
The case for structuring the discussion of scientific papers. BMJ (1999) 4.16
Peer review: reform or revolution? BMJ (1997) 4.13
Complete nucleotide sequence of the 16S rRNA gene of Mycobacterium bovis BCG. J Bacteriol (1988) 4.10
Profile of the GMC: The day of judgment comes closer. BMJ (1989) 4.10
Managing the clinical performance of doctors. A coherent response to an intractable problem. BMJ (1999) 4.08
BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. Gut (2004) 4.06
Effect of blinding and unmasking on the quality of peer review: a randomized trial. JAMA (1998) 4.03
Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol (2001) 3.92
Tumorigenesis by mouse mammary tumor virus: evidence for a common region for provirus integration in mammary tumors. Cell (1983) 3.89
THE ISOLATION OF POLIOMYELITIS VIRUS FROM HUMAN EXTRA-NEURAL SOURCES. III. PERSISTENCE OF VIRUS IN STOOLS AFTER ACUTE INFECTION. J Clin Invest (1946) 3.88
Eosinophilic bronchitis is an important cause of chronic cough. Am J Respir Crit Care Med (1999) 3.84
Coding of modified body schema during tool use by macaque postcentral neurones. Neuroreport (1996) 3.78
Protein kinase activity associated with polyoma virus middle T antigen in vitro. Cell (1979) 3.78
Proposal for a new clinical entity, IgG4-positive multiorgan lymphoproliferative syndrome: analysis of 64 cases of IgG4-related disorders. Ann Rheum Dis (2008) 3.77
Babies sleeping with parents: case-control study of factors influencing the risk of the sudden infant death syndrome. CESDI SUDI research group. BMJ (1999) 3.76
Profile of the GMC. 1978 and all that. BMJ (1989) 3.76
Helicobacter pylori CagA protein can be tyrosine phosphorylated in gastric epithelial cells. J Exp Med (2000) 3.74
"Taken from this place and hanged by the neck...". BMJ (1991) 3.72
Mitochondrial DNA mutations as an important contributor to ageing and degenerative diseases. Lancet (1989) 3.69
The rights of patients in research. BMJ (1995) 3.68
All doctors are problem doctors. BMJ (1997) 3.67
The BMJ's website scales up. BMJ (1998) 3.67
Publishing research supported by the tobacco industry. BMJ (1996) 3.65
Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res (1994) 3.65
How best to organise acute hospital services? BMJ (2001) 3.63
Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet (2000) 3.63
Improving the repeat prescribing process in a busy general practice. A study using continuous quality improvement methodology. Qual Health Care (1999) 3.61
Tumorigenesis by mouse mammary tumor virus: proviral activation of a cellular gene in the common integration region int-2. Cell (1984) 3.61
An Mll-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: a method to create fusion oncogenes. Cell (1996) 3.60
Netprints: the next phase in the evolution of biomedical publishing. BMJ (1999) 3.60
INSECTS AND EPIDEMIOLOGY OF POLIOMYELITIS. Science (1942) 3.59
Unbuffered highly acidic gastric juice exists at the gastroesophageal junction after a meal. Gastroenterology (2001) 3.52